CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $27.59M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 13.88: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.60BUSDvs all stocks (USD)
Revenue (TTM)
27.59MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.23xvs all stocks
52-Week Change
1.52%vs all stocks
Market Capitalization
1.60BUSDvs all stocks (USD)
Enterprise Value
1.31BUSDvs all stocks (USD)
Forward P/E
-7.04xvs Biotechnology peers
Price to Sales (TTM)
57.84xvs Biotechnology peers
Price to Book (MRQ)
4.47xvs Biotechnology peers
Enterprise to Revenue
47.49xvs Biotechnology peers
Enterprise to EBITDA
-5.91xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-701.65%vs Biotechnology peers
Return on Assets (TTM)
-35.87%vs Biotechnology peers
Return on Equity (TTM)
-61.10%vs Biotechnology peers
Revenue (TTM)
27.59MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.4420USDUpdated Sep 28, 2026Quarterly Revenue Growth
-32.50%vs Biotechnology peers
Gross Profit (TTM)
27.59MUSDvs all stocks (USD)
EBITDA (TTM)
-221.63MUSDvs all stocks (USD)
Net Income (TTM)
-207.90MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-32.51%vs Biotechnology peers
Operating Cash Flow (TTM)
-177.99MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-106.20MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
184.42MUSDFY2025 · Dec 31, 2025Operating Income
-20.59MUSDvs all stocks (USD)
Pre-tax Income
-6.88MUSDFY2025 · Dec 31, 2025Net Income
-6.88MUSDFY2025 · Dec 31, 2025EBIT
-20.59MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-18.82MUSDFY2025 · Dec 31, 2025Research & Development
137.92MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
67.09MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-6.88MUSDFY2025 · Dec 31, 2025Operating Cash Flow
25.13MUSDFY2025 · Dec 31, 2025Free Cash Flow
24.46MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
84.94MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-6.88MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.77MUSDFY2025 · Dec 31, 2025Stock-based Compensation
32.24MUSDFY2025 · Dec 31, 2025Other Non-cash Items
2.41MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-4.27MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-130.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-670.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-322.72MUSDFY2025 · Dec 31, 2025Sale of Investments
136.58MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-186.81MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
87.78MUSDFY2025 · Dec 31, 2025Shares Outstanding
62.40MSharesUpdated Sep 28, 2026Float Shares
49.22MSharesUpdated Sep 28, 2026Shares Short
11.15MSharesUpdated Sep 28, 2026Short Ratio
13.74daysvs all stocks
Short % of Shares Outstanding
17.95%vs all stocks
% Held by Insiders
3.68%vs all stocks
% Held by Institutions
123.59%vs all stocks
Total Cash (MRQ)
292.82MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
4.54USDUpdated Sep 28, 2026Total Debt (MRQ)
2.68MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0078xvs Biotechnology peers
Current Ratio (MRQ)
7.69xvs Biotechnology peers
Book Value per Share (MRQ)
5.54USDUpdated Sep 28, 2026Total Assets
418.43MUSDvs all stocks (USD)
Total Current Assets
305.70MUSDFY2025 · Dec 31, 2025Total Liabilities
65.98MUSDFY2025 · Dec 31, 2025Total Non-current Assets
112.73MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
8.10MUSDFY2025 · Dec 31, 2025Total Current Liabilities
57.88MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
84.22MUSDFY2025 · Dec 31, 2025Other Short-term Investments
200.45MUSDFY2025 · Dec 31, 2025Accounts Receivable
5.94MUSDFY2025 · Dec 31, 2025Accounts Payable
4.94MUSDFY2025 · Dec 31, 2025Short-term Debt
3.01MUSDFY2025 · Dec 31, 2025Deferred Revenue
11.90MUSDFY2025 · Dec 31, 2025Other Current Liabilities
1.06MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
1.14MUSDFY2025 · Dec 31, 2025Common Stock (Book)
5.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-497.71MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
352.46MUSDvs all stocks (USD)
52-Week Low
20.32USDUpdated Sep 28, 202652-Week High
40.22USDUpdated Sep 28, 202652-Week Change
1.52%vs all stocks
Beta
1.23xvs all stocks
50-Day MA
30.21USDUpdated Sep 28, 2026200-Day MA
31.82USDUpdated Sep 28, 2026Avg 10-Day Volume
910.20KSharesUpdated Sep 28, 2026Avg 30-Day Volume
834.95KSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-3.39USDUpdated Sep 28, 2026Other Income / Expense
-51.00KUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 13.88: safe zoneNotable
Altman Z-Score: 13.88
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $27.59M, lower than 95% of all stocks globallySignificant
Revenue (USD): 27,588,000Global P5: 33,357,653.812
Market cap is $1.6B, above the global median of $1.18BNotable
Market cap (USD): 1,600,250,801Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Shanghai Opm Biosciences Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Natco Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Staidson (Beijing) Biopharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Jingfeng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Consun Pharmaceutical Group Limited
Tier 1ProductionApproval-Gated PipelineRule
Syndax Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
BeBetter Med Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Henan Lingrui Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sihuan Pharmaceutical Holdings Group Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai MicroPort Endovascular MedTech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule